Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout Mice
Authors:
Open Access
- 31 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 52 (6) , 2001-2011
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity that can progress to nonalcoholic steatohepatitis (NASH), a serious liver pathology that can advance to cirrhosis. The mechanisms responsible for NAFLD progression to NASH remain unclear. Lack of a suitable animal model that faithfully recapitulates the patho-physiology of human NASH is a major obstacle in delineating mechanisms responsible for progression of NAFLD to NASH and, thus, development of better treatment strategies. We identified and characterized a novel mouse model, middle-aged male low-density lipopro-tein receptor ( LDLR) 2/2 mice fed a high-fat diet (HFD), which developed NASH associ-ated with four of five metabolic syndrome (MS) components. In these mice, as observed in humans, liver steatosis and oxidative stress promoted NASH development. Aging exacer-bated the HFD-induced NASH such that liver steatosis, inflammation, fibrosis, oxidative stress, and liver injury markers were greatly enhanced in middle-aged versus young LDLR 2/2 mice. Although expression of genes mediating fatty acid oxidation and antioxi-dant responses were up-regulated in young LDLR 2/2 mice fed HFD, they were drastically reduced in MS mice. However, similar to recent human trials, NASH was partially attenu-ated by an insulin-sensitizing peroxisome proliferator-activated receptor-gamma (PPARc) ligand, rosiglitazone. In addition to expected improvements in MS, newly identified mech-anisms of PPARc ligand effects included stimulation of antioxidant gene expression and mitochondrial b-oxidation, and suppression of inflammation and fibrosis. LDLR-defi-ciency promoted NASH, because middle-aged C57BL/6 mice fed HFD did not develop severe inflammation and fibrosis, despite increased steatosis. Conclusion: MS mice repre-sent an ideal model to investigate NASH in the context of MS, as commonly occurs in human disease, and NASH development can be substantially attenuated by PPARc activa-tion, which enhances b-oxidation. (HEPATOLOGY 2010;52:2001-2011)Keywords
This publication has 29 references indexed in Scilit:
- Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension TrialHepatology, 2010
- In Situ Lipidomic Analysis of Nonalcoholic Fatty Liver by Cluster TOF-SIMS ImagingAnalytical Chemistry, 2009
- NF-E2-Related Factor 2 Inhibits Lipid Accumulation and Oxidative Stress in Mice Fed a High-Fat DietThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Prediction of coronary atherosclerotic disease with liver transaminase levelLiver International, 2007
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisHepatology, 2007
- Differential gene expression in periportal and perivenous mouse hepatocytesThe FEBS Journal, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic processInternational Journal of Experimental Pathology, 2004
- The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistanceJournal of Hepatology, 2004
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisHepatology, 1999